Navigation Links
Irritable bowel syndrome can have genetic causes
Date:12/10/2008

Irritations of the bowel can have genetic causes. Researchers at the Institute of Human Genetics at Heidelberg University Hospital have discovered this correlation. The causes of what is known as irritable bowel syndrome (IBS), one of the most common disorders of the gastrointestinal tract, are considered unclear making diagnosis and treatment extremely difficult. The results from Heidelberg, which were published in the prestigious jour-nal "Human Molecular Genetics", improve the outlook for an effective medication against a disease that is frequently played down as a func-tional disorder.

In Germany, approximately five million people are affected by IBS, women about twice as often as men. But only around 20 percent of these people even consult a physician. Many patients suffer from constipation, others from severe diarrhea, or a combination of both. The illness affects the general condition and quality of life of these patients and often lasts for months or even years.

Modified receptors lead to overstimulation of the bowel

Serotonin plays an important role in the complex processes in the diges-tive tract just as it affects sleep, mood, and blood pressure. Various types of receptors are located in the intestine, to which serotonin attaches according to the lock and key principle and thus transmits cellular signals.

"We have determined that patients who suffer from irritable bowel syn-drome with diarrhea show a higher frequency of certain mutations ", ex-plains Dr. Beate Niesler, who investigates the genetic causes of complex diseases with her team in the Department of Human Molecular Genetics (Director: Prof. Gudrun Rappold) at the Heidelberg Institute of Human Genetics. These mutations appear to cause changes in the composition or number of receptors on the cell surface. "The signal transduction in the digestive tract may be disturbed and this may lead to overstimulation of the intestine. Resulting disturbances in fluid balance could explain the occurrence of diarrhea", says Johannes Kapeller, a PhD student in the team.

Medication blocks serotonin receptors

The serotonin receptor blocker Alosetron is only approved in the US where it is effectively used in the treatment of women suffering from diarrhea-predominant IBS, but can only be prescribed with strict limitations due to its side effects. Alosetron inhibits the serotonin receptors in the intestinal tract and thus slows the movement of the bowels.

"Currently, patients with irritable bowel syndrome are treated on a trial and error basis"", explains Dr. Beate Niesler. The Heidelberg data could contribute to development and prescription of specific medications for certain genetic mutations in patients.

Correlation with depression and pain

Research of the serotonin system shows interesting correlations sero-tonin receptors are located on neural transduction pathways involved in pain perception and influence them which could explain why patients with irritable bowel syndrome often complain of severe pain although no pathological changes such as infections or tumors are present. It has also been noted that persons with modified receptors suffer more frequently from depression.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
0049-622-156-4536
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. Is yakult helpful in the treatment of irritable bowel syndrome?
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Scientists successfully treat new mouse model of inflammatory bowel disease
4. New genes found for inflammatory bowel disease in children
5. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
6. Researchers identify proteins involved in new neurodegenerative syndrome
7. Restless legs syndrome affects nearly 2 percent of US/UK children
8. Obesity-related hormone is higher in children with Down syndrome
9. Rare cancer-causing syndrome found, for the first time, in Singapore
10. Effective ADHD treatment found for children with fragile X syndrome
11. Study suggests new way to screen infants for fetal alcohol syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology: